Literature DB >> 12407444

Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2.

S M Messerli1, Y Tang, M Giovannini, R Bronson, R Weissleder, X O Breakefield.   

Abstract

Spontaneous schwannomas were detected by magnetic resonance imaging (MRI) in a transgenic murine model of neurofibromatosis type 2 (NF2) expressing a dominant mutant form of merlin under the Schwann cell-specific P0 promoter. Approximately 85% of the investigated mice showed putative tumors by 24 months of age. Specifically, 21% of the mice showed tumors in the intercostal muscles, 14% in the limb muscles, 7% in the spinal cord and spinal ganglia, 7% in the external ear, 14% in the muscle of the abdominal region, and 7% in the intestine; 66% of the female mice had uterine tumors. Multiple tumors were detected by MRI in 21% of mice. The tumors were isointense with muscle by T1-weighted MRI, showed strong enhancement following administration of gadolinium-DTPA, and were markedly hyperintense by T2-weighted MRI, all hallmarks of the clinical manifestation. Hematoxylin and eosin staining and immunohistochemistry indicated that the tumors consisted of schwannomas and Schwann cell hyperplasias. The lesions stained positively for S-100 protein and a marker antigen for the mutated transgenic NF2 protein, confirming that the imaged tumors and areas of hyperplasia were of Schwann cell origin and expressed the mutated NF2 protein. Tumors were highly infectable with a recombinant herpes simplex virus type 1 vector, hrR3, which contains the reporter gene, lacZ. The ability to develop schwannoma growth with a noninvasive imaging technique will allow assessment of therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407444      PMCID: PMC1503664          DOI: 10.1038/sj.neo.7900265

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  39 in total

1.  Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.

Authors:  A I McClatchey; I Saotome; K Mercer; D Crowley; J F Gusella; R T Bronson; T Jacks
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

2.  Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer.

Authors:  J Price; D Turner; C Cepko
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

3.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin.

Authors:  R J Shaw; A I McClatchey; T Jacks
Journal:  Cell Growth Differ       Date:  1998-04

Review 5.  Gene therapy for high grade gliomas.

Authors:  J B Alavi; S L Eck
Journal:  Expert Opin Biol Ther       Date:  2001-03       Impact factor: 4.388

6.  Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane.

Authors:  B Deguen; P Mérel; L Goutebroze; M Giovannini; H Reggio; M Arpin; G Thomas
Journal:  Hum Mol Genet       Date:  1998-02       Impact factor: 6.150

7.  MR findings in primary retroperitoneal schwannoma.

Authors:  K Hayasaka; Y Tanaka; S Soeda; P Huppert; C D Claussen
Journal:  Acta Radiol       Date:  1999-01       Impact factor: 1.990

8.  Central neurofibromatosis with bilateral acoustic neuroma.

Authors:  R Eldridge
Journal:  Adv Neurol       Date:  1981

9.  Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.

Authors:  S S Yoon; N M Carroll; E A Chiocca; K K Tanabe
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Microinjected antibodies against the cytoplasmic domain of vesicular stomatitis virus glycoprotein block its transport to the cell surface.

Authors:  T E Kreis
Journal:  EMBO J       Date:  1986-05       Impact factor: 11.598

View more
  8 in total

1.  Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Authors:  Sherif G Ahmed; Ahmed Abdelnabi; Casey A Maguire; Mohamed Doha; Jessica E Sagers; Rebecca M Lewis; Alona Muzikansky; Marco Giovannini; Anat Stemmer-Rachamimov; Konstantina M Stankovic; Giulia Fulci; Gary J Brenner
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

Review 2.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

3.  Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.

Authors:  Shilpa Prabhakar; Mehran Taherian; Davide Gianni; Thomas J Conlon; Giulia Fulci; Jillian Brockmann; Anat Stemmer-Rachamimov; Miguel Sena-Esteves; Xandra O Breakefield; Gary J Brenner
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

4.  The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.

Authors:  Iddo Paldor; Sara Abbadi; Nicolas Bonne; Xiaobu Ye; Fausto J Rodriguez; David Rowshanshad; MariaLisa Itzoe; Veronica Vigilar; Marco Giovannini; Henry Brem; Jaishri O Blakeley; Betty M Tyler
Journal:  J Neurooncol       Date:  2017-07-22       Impact factor: 4.130

5.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

6.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

7.  Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

Authors:  D Gareth Evans; Marco Giovannini; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery; James H Tonsgard; D Bradley Welling; Brigitte Widemann; Kaleb Yohay
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

8.  Schwannoma Gene Therapy via Adeno-Associated Viral Vector Delivery of Apoptosis-Associated Speck-like Protein Containing CARD (ASC): Preclinical Efficacy and Safety.

Authors:  Sherif G Ahmed; Casey A Maguire; Shiliang Alice Cao; Gary J Brenner
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.